MDT-AP-1367
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 22.919999999999998
- os_event
- false
- age_years
- 8.13
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.343594343
- umap2_2d
- 3.795151428
- umap1_3d
- 2.597901397
- umap2_3d
- -2.134786923
- umap3_3d
- -2.24831813
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.350
- G2M_CHECKPOINT+0.310
- E2F_TARGETS+0.250
- SPERMATOGENESIS+0.220
- WNT_BETA_CATENIN_SIGNALING+0.150
- PROTEIN_SECRETION+0.140
- KRAS_SIGNALING_DN+0.120
- HEME_METABOLISM+0.070
- TGF_BETA_SIGNALING+0.070
- UV_RESPONSE_DN+0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.470
- ALLOGRAFT_REJECTION-0.450
- INFLAMMATORY_RESPONSE-0.390
- COMPLEMENT-0.380
- IL6_JAK_STAT3_SIGNALING-0.380
- TNFA_SIGNALING_VIA_NFKB-0.380
- INTERFERON_GAMMA_RESPONSE-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- APOPTOSIS-0.350
- MYC_TARGETS_V1-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A3IZ-01A-11R-A213-07 | — | B | 0.897 |
| 2 | MDT-AP-3325 | Med | Medulloblastoma | 0.850 |
| 3 | MNG214 | — | — | 0.847 |
| 4 | MDT-AP-3265 | Med | Medulloblastoma | 0.846 |
| 5 | BS_W311713R | medulloblastoma | — | 0.835 |
| 6 | TCGA-CN-4741-01A-01R-1436-07 | — | — | 0.834 |
| 7 | TCGA-CR-7402-01A-11R-2016-07 | — | — | 0.832 |
| 8 | SJEPD031175_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.832 |
| 9 | TCGA-OR-A5K4-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.828 |
| 10 | BS_2SFTWNVE | medulloblastoma | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |